LFG
BBC icon

Larson Financial Group’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Larson Financial Group’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$832 Hold
20
– – ﹤0.01% 3211
2025
Q4 		$771 Buy
+20
New +$679 ﹤0.01% 3023

Other funds holding BBC

KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MCM
Militia Capital Management Austin, Texas $454M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
APW
Aurora Private Wealth Rockaway, New Jersey $140M AUM
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Larson Financial Group's BBC Position: Q1 2026 in Review

Larson Financial Group held its Virtus Biotech Clinical Trials ETF (BBC) position steady in Q1 2026 at 20 shares worth $832. The position accounts for ﹤0.01% of the portfolio, ranked #3211.

Larson Financial Group first reported a position in BBC in Q4 2025 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold BBC as of Q1 2026.

  • Larson Financial Group held 20 shares of Virtus Biotech Clinical Trials ETF worth $832 as of Q1 2026.
  • Larson Financial Group left its Virtus Biotech Clinical Trials ETF share count unchanged in Q1 2026.
  • Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3211 holding.
  • Larson Financial Group first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2025 and has held it in 2 quarters since.
  • 20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.